Xeris Biopharma Reports Record Q4 and Full-Year 2024 Results, Sets 2025 Guidance Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a rapidly growing biopharmaceutical company dedicated to improving patient lives by developing and commercializing innovative therapies, has announced record-breaking financial results for…
Italfarmaco Updates on Givinostat for Duchenne Muscular Dystrophy Italfarmaco S.p.A., a global pharmaceutical company dedicated to developing innovative treatments for rare diseases, has provided a comprehensive update on the regulatory and clinical advancements of givinostat, its investigational therapy for Duchenne…
Alnylam Announces Retirement of Co-Founder and Esteemed Board Member Dr. Phillip A. Sharp Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the pioneering leader in RNA interference (RNAi) therapeutics, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company’s Board…
Orbis Medicines Appoints Industry Veteran Mikael Dolsten as Board Chair Orbis Medicines, a pioneering leader in oral macrocycle drug discovery, has announced the appointment of Mikael Dolsten, M.D., Ph.D., as Chairperson of the Board of Directors. Dr. Dolsten, the former…
Bionova Launches New Process Development and Pilot Plant in Fremont Bionova Scientific, an Asahi Kasei company and boutique commercial-scale biologics contract development and manufacturing organization (CDMO), has officially announced the opening of a new state-of-the-art facility in Fremont, California. Spanning…
Cadrenal Therapeutics Partners with Abbott for Pivotal Tecarfarin Study in HeartMate 3™ LVAD Patients Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company specializing in the development of cardiovascular therapeutics, has announced a collaboration agreement with Abbott (NYSE: ABT) to…
NationsBenefits® Reinforces Nutrition-First Approach to GLP-1 Support During National Nutrition Month As National Nutrition Month brings attention to the critical role of healthy eating in disease prevention and overall wellness, NationsBenefits® is reaffirming its commitment to nutrition-first healthcare solutions. Through…
Centauri Therapeutics Advances Lead Immunotherapy for Gram-Negative Infections Centauri Therapeutics Limited (Centauri), a pioneering immunotherapy company with a proprietary platform technology applicable across multiple therapeutic areas, has announced the selection of its first clinical candidate in the ABX-01 program. This…
Guardian Pharmacy Services Reports Preliminary Q4 and Full-Year 2024 Results, Provides 2025 Guidance Guardian Pharmacy Services, Inc. (“Guardian” or the “Company”) (NYSE: GRDN), one of the largest long-term care (LTC) pharmacy services companies in the United States, has announced its…
Wedgewood Names Jessica Knopp-Gwynne Chief Revenue Officer to Lead Strategic Growth Wedgewood, the nation’s largest provider of compounded veterinary medications and pharmacy solutions, has appointed Jessica Knopp-Gwynne as Chief Revenue Officer (CRO). With extensive experience in revenue growth, commercial strategy,…
Arrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day Arrowhead Pharmaceuticals Expands “We’ll Get There Soon” Campaign with New Resources for Familial Chylomicronemia Syndrome on Rare Disease Day Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is marking Rare Disease Day with…
Vertex Gains CHMP Nod for KAFTRIO® Label Expansion in Rare CF Mutations Vertex Pharmaceuticals (Nasdaq: VRTX) has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the expansion…